Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04083742 · ClinicalTrials.gov registry record

The Heidelberg Engineering ANTERION Anterior Segment Metrics Precision and Agreement Study

A clinical trial, sponsored by Heidelberg Engineering.

Completed
Registry status
59
Enrollment target

NCT04083742: Completed study, sponsored by Heidelberg Engineering.

NCT04083742 is a clinical trial that has completed, run by Heidelberg Engineering. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04083742 has completed, sponsored by Heidelberg Engineering.

COMPLETED
Registry status
59 participants
Enrollment target

Study Summary

This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess anterior segment metrics with the ANTERION

Primary Outcome

Reproducibility and repeatability of Spur to Spur distance parameter \[mm\] of ANTERION and the reference device

Interventions

  • DEVICE ANTERION

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2019-08-22
Est. Completion 2023-12-31
Heidelberg Engineering

16 total trials

What the finished NCT04083742 record still lists

NCT04083742 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which ANTERION is the first listed.

NCT04083742 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04083742 about?

NCT04083742 is a clinical study titled "The Heidelberg Engineering ANTERION Anterior Segment Metrics Precision and Agreement Study". This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess anterior segment metrics with the ANTERION

What is the current status of trial NCT04083742?

This trial is currently completed. The enrollment target is 59 participants. The study started on 2019-08-22. Estimated completion is 2023-12-31.

What interventions are being tested in trial NCT04083742?

The interventions under investigation include: ANTERION (DEVICE).

Who is sponsoring clinical trial NCT04083742?

This trial is sponsored by Heidelberg Engineering, which has 16 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03801083 · 59 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

  • NCT04332367 · 59 participants · Phase 2

    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • NCT05489575 · 59 participants · NA

    CPAP for the Treatment of Supine Hypertension

  • NCT06721689 · 59 participants · Phase 1

    PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04083742, the US trial registry maintained by the National Library of Medicine. NCT04083742 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.